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13.02.002Abstract Candidate protein biomarker discovery by full automatic integration of Orbitrap full
MS1 spectral peptide proﬁling and X!Tandem MS2 peptide sequencing is investigated by analyzing
mass spectra from brain tumor samples using Peptrix. Potential protein candidate biomarkers
found for angiogenesis are compared with those previously reported in the literature and obtained
from previous Fourier transform ion cyclotron resonance (FT-ICR) peptide proﬁling. Lower mass
accuracy of peptide masses measured by Orbitrap compared to those measured by FT-ICR is com-
pensated by the larger number of detected masses separated by liquid chromatography (LC), which
can be directly linked to protein identiﬁcations. The number of peptide sequences divided by the
number of unique sequences is 9248/6911  1.3. Peptide sequences appear 1.3 times redundant
per up-regulated protein on average in the peptide proﬁle matrix, and do not seem always up-reg-
ulated due to tailing in LC retention time (40%), modiﬁcations (40%) and mass determination
errors (20%). Signiﬁcantly up-regulated proteins found by integration of X!Tandem are described
in the literature as tumor markers and some are linked to angiogenesis. New potential biomarkers
are found, but need to be validated independently. Eventually more proteins could be found by
actively involving MS2 sequence information in the creation of the MS1 peptide proﬁle matrix.Introduction
Orbitrap mass spectrometry (MS) plays an increasingly impor-
tant role in proteomics research. Orbitrap combines great massaer MK).
eijing Institute of Genomics,
tics Society of China.
ng by Elsevier
jing Institute of Genomics, Chinese Aaccuracy (<10 ppm) with a high processing speed for peptide
mixtures separated by nano-liquid chromatography (nano-
LC). A comparable instrument, the Fourier transform ion
cyclotron resonance (FT-ICR) mass spectrometer, has a
slightly better mass accuracy of 6 1 ppm [1]. However, the per-
formance of FT-ICR depends on the magnet strength chosen,
e.g., 9.4 T, and thus it takes up a lot more space because of the
sizeable magnet. Orbitrap has a shorter time scale of measur-
ing than FT-ICR and can therefore be more conveniently
linked to a nano-LC column to measure peptide fractions of
a trypsin-digested sample.
Comparison of mass spectra from different samples is
called peptide proﬁling. Peptide proﬁling creates a matrix ofcademy of Sciences and Genetics Society of China. Production and hosting
Figure 1 Architecture of Peptrix
Peptrix processes raw Orbitrap ﬁles to a peptide proﬁle matrix of all the intensities measured for every peptide mass with a certain
retention time in the different samples with protein identiﬁcations. Peptrix implements Readw.exe (version 4.3.1), *.fasta ﬁle, and
tandem.exe. Peptrix generates a Mascot generic ﬁle (MGF) for each Orbitrap ﬁle. The *.fasta ﬁle is the text database to correlate MS2
fragmentation masses to a protein.
Titulaer MK / Integration Peptide Proﬁling and MS2 Sequencing 183
Table 1 Differentially expressed peptides of proteins between GV and NV groups
Mass MH+ (Da) Time (s) Calculated MH+ (Da) ppm Mod Sequence Miss P Up Ave. intensity ( · 100)
GV/NV GV NV
sp|O00468|AGRIN_HUMAN agrin
1051.5951 11,281 1051.5935 1.5 SFLAFPTLR 0 0.0022 + High 124 0
1154.6514 6352 1154.6527 1.1 LELGIGPGAATR 0 0.1207 + 3.1 364 117
1188.6501 8036 1205.7000 19.4 1 QLLTPEHVLR 0 0.0448 + 2.2 552 255
1246.6788 5956 1246.6790 0.2 GPSGLLLYNGQK 0 0.9692  0.8 175 215
1295.6452 15,752 1295.6477 1.9 SIESTLDDLFR 0 0.0283 + 13.8 219 16
1323.6219 5687 1323.6175 3.3 SAGDVDTLAFDGR 0 0.0072 + 11.7 4942 422
1628.8763 9105 1628.8754 0.6 ALEPQGLLLYNGNAR 0 0.0110 + 10.5 145 14
sp|O75891|AL1L1_HUMAN aldehyde dehydrogenase family 1 member L1
1363.6835 10,783 1363.6852 1.2 DLGEAALNEYLR 0 0.0060 + High 146 0
1787.9414 5112 1787.9174 13.4 LPQPEEGATYEGIQKK 1 0.0187 + 39.1 312 8
tr|E9PR44|E9PR44_HUMAN Uncharacterized protein (CRYAB_HUMAN.alpha-crystallin B chain)
921.5027 5749 921.5040 1.4 FSVNLDVK 0 0.0858 + 8.7 431 50
921.5040 7157 921.5040 0.0 FSVNLDVK 0 0.0277 + 3.6 2940 820
1213.6566 5147 1213.6575 0.7 HFSPEELKVK 1 0.0058 + 18.2 2431 134
1454.8235 5121 1454.8213 1.5 5 TIPITREEKPAVT 2 0.0403 + 28.4 257 9
1822.0476 5108 1822.0432 2.4 TIPITREEKPAVTAAPK 2 0.0022 + High 907 0
tr|E9PJL7|E9PJL7_HUMAN Uncharacterized protein (CRYAB_HUMAN.alpha-crystallin B chain)
1374.7080 5710 1374.7065 1.1 RPFFPFHSPSR 1 0.0022 + High 461 0
1446.7278 7155 1388.7255 5.5 2,3 MDIAIHHPWIR 0 0.1183 + 14.8 867 59
1639.7568 5629 1639.7571 0.2 HEERQDEHGFISR 1 0.0079 + 20.5 358 17
1716.9039 5148 1716.9027 0.7 VLGDVIEVHGKHEER 1 0.0376 + 2.4 1745 733
tr|E9PNH7|E9PNH7_HUMAN Uncharacterized protein (CRYAB_HUMAN.alpha-crystallin B chain)
1165.6595 5443 1165.6575 1.7 VLGDVIEVHGK 0 0.0100 + 14.6 1054 72
tr|E7ETU3|E7ETU3_HUMAN Uncharacterized protein (cell division control protein 42 homolog)
1224.6482 6133 1241.6736 0.9 1 QKPITPETAEK 1 0.7910 + 1.1 168 153
1472.8491 13,709 1472.8471 1.4 TPFLLVGTQIDLR 0 0.0298 + 17.2 109 6
sp|P10909|CLUS_HUMAN clusterin
1117.6073 7057 1117.6099 2.3 TLLSNLEEAK 0 0.0125 + 25.5 876 34
1245.6996 5854 1245.7049 4.3 TLLSNLEEAKK 1 0.0146 + 80.7 1019 13
1296.7549 7499 1296.7521 2.2 6 PITVTVPVEVSR 0 0.0060 + High 460 0
1360.7441 5927 1360.7430 0.8 TLIEKTNEERK 2 0.5036 + 58.5 288 5
1373.8000 5205 1373.7998 0.1 KTLLSNLEEAKK 2 0.0022 + High 1404 0
1575.8515 5619 1575.8489 1.6 YVNKEIQNAVNGVK 1 0.0022 + High 417 0
1576.8315 5260 1575.8489 0.9 4 YVNKEIQNAVNGVK 1 0.0426 + 14.4 621 43
1842.8973 5748 1842.9079 5.8 7 SHTSDSDVPSGVTEVVVK 0 0.1564  0.4 52 125
1873.9827 12,680 1873.9905 4.2 LFDSDPITVTVPVEVSR 0 0.0187 + 141.2 1721 12
2009.8660 6065 2009.8716 2.8 DQTVSDNELQEMSNQGSK 0 0.0889 + 14 1469 105
2010.8479 6275 2009.8716 3.8 4 DQTVSDNELQEMSNQGSK 0 0.0666 + 18.2 246 14
2025.8692 6109 2009.8716 0.9 2 DQTVSDNELQEMSNQGSK 0 0.0077 + 14.5 400 28
tr|B4DN87|B4DN87_HUMAN Uncharacterized protein (collagen-binding protein 2 P50454)
1224.6574 5092 1224.6582 0.7 GVVEVTHDLQK 0 0.1613 + 1.5 353 239
1337.7452 6553 1337.7423 2.2 HLAGLGLTEAIDK 0 0.1722 + 8.4 102 12
1659.8017 11,433 1659.8013 0.2 LYGPSSVSFADDFVR 0 0.3059 + 16.2 409 25
1887.0880 9896 1887.0810 3.7 DTQSGSLLFIGRLVRPK 2 0.0779 + High 65 0
tr|B4DF14|B4DF14_HUMAN Uncharacterized protein (excitatory amino acid transporter 1)
1723.7509 6962 1723.7513 0.2 DVEMGNSVIEENEMK 0 0.0139 + 11.8 168 14
1739.7299 6837 1723.7513 12.1 2 DVEMGNSVIEENEMK 0 0.0229 + 16.3 449 28
2040.0745 11,079 2040.0720 1.2 TTTNVLGDSLGAGIVEHLSR 0 0.0060 + High 211 0
sp|Q16658|FSCN1_HUMAN fascin
1076.5133 5760 1076.5119 1.3 YSVQTADHR 0 0.2247 + 2.3 272 120
1076.5315 5880 1076.5119 18.2 YSVQTADHR 0 0.5149  0.2 1159 4652
1190.6392 5446 1190.6415 1.9 YLAPSGPSGTLK 0 0.0448 + 2.7 404 148
1200.6740 5289 1200.6735 0.4 YLKGDHAGVLK 1 0.0489 + 5.6 241 43
1240.7888 6908 1240.7888 0.0 LINRPIIVFR 1 0.0008 + High 225 0
1819.9725 7243 1819.9701 1.3 LVARPEPATGYTLEFR 1 0.1012 + 48.2 294 6
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Table 1 continued
Mass MH+ (Da) Time (s) Calculated MH+ (Da) ppm Mod Sequence Miss P Up Ave. intensity ( · 100)
GV/NV GV NV
sp|O15540|FABP7_HUMAN fatty acid-binding protein, brain
963.5163 5668 963.5258 9.9 8 TFGDVVAVR 0 0.3994 + 2.2 279 129
1489.6637 6212 1489.6628 0.6 LTNSQNFDEYMK 0 0.0008 + High 676 0
1489.6672 5901 1489.6628 3.0 LTNSQNFDEYMK 0 0.1826  0.4 58 157
1505.6539 6215 1489.6628 5.6 2 LTNSQNFDEYMK 0 0.0022 + High 324 0
1554.8059 12,106 1538.8069 0.3 2 MVMTLTFGDVVAVR 0 0.8942 + 1.9 26 14
1637.9231 6219 1637.9220 0.7 SVVSLDGDKLVHIQK 1 0.0147 + 137.3 474 3
1896.0122 7155 1913.0338 2.6 1 QVGNVTKPTVIISQEGDK 1 0.0149 + High 53 0
2363.3206 9030 2380.3558 3.7 1 QVGNVTKPTVIISQEGDKVVIR 2 0.0149 + High 113 0
2380.3550 7027 2380.3558 0.3 QVGNVTKPTVIISQEGDKVVIR 2 0.0837 + 215.1 379 2
sp|P49327|FAS_HUMAN fatty acid synthase
1038.6568 7667 1038.6557 1.1 GTPLISPLIK 0 0.0403 + 30.6 119 4
1115.6675 8470 1115.6670 0.4 SEGVVAVLLTK 0 0.0350 + High 30 0
1263.7421 6778 1263.7419 0.2 LQVVDQPLPVR 0 0.0299 + 2.6 123 47
1298.6487 5094 1298.6699 16.3 VGDPQELNGITR 0 0.2694 + 6.9 582 84
1308.6212 14,642 1250.6119 0.6 3,2 MEEVVIAGMSGK 0 0.0041 + 9.7 49 5
1386.7491 9654 1386.7474 1.2 GVDLVLNSLAEEK 0 0.0030 + 9 82 9
1426.7769 8686 1426.7722 3.3 SLLVNPEGPTLMR 0 0.0366 + 22 113 5
1469.6989 7733 1469.7019 2.0 FPQLDSTSFANSR 0 0.0522 + 4.9 97 20
1622.9367 10,585 1622.9363 0.2 VVVQVLAEEPEAVLK 0 0.0366 + 11.1 69 6
tr|E9PE77|E9PE77_HUMAN Uncharacterized protein (FINC_HUMAN. ﬁbronectin)
808.4306 5311 808.4312 0.7 AQITGYR 0 0.0530 + 6.3 641 101
997.5225 5423 997.5200 2.5 9 TKTETITGF 1 0.9356 + 1.4 219 152
1109.5254 6194 1109.5221 3.0 10 SSGSGPFTDVR 0 0.9097 + 1.3 274 208
1110.5407 5185 1110.5426 1.7 STTPDITGYR 0 0.7913 + 1.8 4345 2454
1113.6136 5923 1113.6150 1.3 11 STAIPAPTDLK 0 0.0639 + 3.8 452 118
1275.6244 5075 1275.6116 10.0 TYHVGEQWQK 0 0.0113  0.3 685 2203
1283.7390 5171 1283.7317 5.7 12 LVAIKGNQESPK 1 0.0350 + High 62 0
1293.6728 8904 1292.6732 12.1 4 DLQFVEVTDVK 0 0.1010 + 3.9 109 28
1323.6652 7053 1323.7127 35.9 LGVRPSQGGEAPR 1 0.0385 + 3.3 288 88
1323.6722 5683 1323.7127 30.6 LGVRPSQGGEAPR 1 0.0746 + 4.3 6728 1560
1323.6730 5297 1323.7127 30.0 LGVRPSQGGEAPR 1 0.1036  0.8 8441 10,627
1323.6737 14,140 1323.7127 29.5 LGVRPSQGGEAPR 1 0.1975  0.6 23 37
1341.6769 5739 1341.6757 0.9 DGQERDAPIVNK 1 0.9699 + 1.1 1779 1600
1341.6773 7209 1341.6757 1.2 DGQERDAPIVNK 1 0.2247 + 2.5 1240 504
1355.6969 7262 1355.6954 1.1 IYLYTLNDNAR 0 0.0521 + 12.9 2909 226
1356.6406 6614 1356.6668 19.3 HHPEHFSGRPR 1 0.2083 + 46.1 187 4
1356.6728 6473 1356.6668 4.4 HHPEHFSGRPR 1 0.0125 + 10.5 409 39
1357.6465 5734 1357.6859 29.0 IAWESPQGQVSR 0 0.0051 + 9.9 1966 199
1379.7041 7364 1379.7052 0.8 GLAFTDVDVDSIK 0 0.5907  0.5 55 114
1431.7515 5652 1431.7491 1.7 WSRPQAPITGYR 1 0.1028 + 21.1 3335 158
1461.7908 6160 1461.7907 0.1 VPGTSTSATLTGLTR 0 0.2729 + 4.8 3209 670
1543.7547 7635 1543.7638 5.9 SYTITGLQPGTDYK 0 0.1354  0.4 97 247
1543.7706 6869 1543.7638 4.4 SYTITGLQPGTDYK 0 0.0290 + 14.9 2740 184
1591.8081 5246 1591.8074 0.4 GDSPASSKPISINYR 1 0.0530 + 10.9 3078 283
1593.8131 8693 1593.8118 0.8 VTDATETTITISWR 0 0.0837 + 27.1 246 9
1593.8246 9706 1593.8118 8.0 VTDATETTITISWR 0 0.3219 + 1.5 52 36
1629.8716 7026 1629.8707 0.6 VDVIPVNLPGEHGQR 0 0.0111 + 39.8 875 22
1732.9435 9993 1732.9479 2.5 NLQPASEYTVSLVAIK 0 0.0858 + 21.3 744 35
1768.9796 5514 1768.9816 1.1 IGFKLGVRPSQGGEAPR 2 0.0049 + 692.4 1426 2
1819.0136 5600 1819.0112 1.3 ITGYIIKYEKPGSPPR 2 0.0366 + 88.4 1853 21
1863.8806 5183 1863.8831 1.3 HTSVQTTSSGSGPFTDVR 0 0.1494 + 5.2 845 163
1913.9780 9350 1912.9974 1.8 4 SSPVVIDASTAIDAPSNLR 0 0.0803 + 7.9 140 18
1955.0102 8432 1955.0080 1.1 EESPLLIGQQSTVSDVPR 0 0.4509 + 7 151 22
2168.0326 9262 2168.0506 8.3 ITYGETGGNSPVQEFTVPGSK 0 0.6087  1 44 45
2478.2029 6598 2462.2079 1.8 2 TEIDKPSQMQVTDVQDNSISVK 1 0.2627 + 9.2 354 38
2478.2034 6016 2462.2079 1.6 2 TEIDKPSQMQVTDVQDNSISVK 1 0.0585 + 2 359 183
2573.3187 7827 2572.3365 0.7 4 TKTETITGFQVDAVPANGQTPIQR 1 0.2755 + 37.1 1167 31
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Table 1 continued
Mass MH+ (Da) Time (s) Calculated MH+ (Da) ppm Mod Sequence Miss P Up Ave. intensity ( · 100)
GV/NV GV NV
sp|Q13423|NNTM_HUMAN NAD(P) transhydrogenase, mitochondrial
953.5322 5046 953.5315 0.7 FGIHPVAGR 0 0.0366 + 10.4 127 12
1072.6238 6122 1072.6248 0.9 EVLASDLVVK 0 0.0149 + High 123 0
1270.6883 7837 1270.6889 0.5 SLGAEPLEVDLK 0 0.0049 + 15.8 86 5
1429.7437 5824 1429.7434 0.2 GITHIGYTDLPSR 0 0.0277 + 4.8 191 40
1524.9084 9253 1524.9107 1.5 ILIVGGGVAGLASAGAAK 0 0.0237 + 7.6 151 20
1561.7473 8847 1578.7758 1.3 1 QGFNVVVESGAGEASK 0 0.0060 + High 53 0
sp|O43175|SERA_HUMAN D-3-phosphoglycerate dehydrogenase
1099.6110 6981 1099.6105 0.5 GGIVDEGALLR 0 0.0022 + 93.5 7167 77
1298.7301 6156 1298.7314 1.0 ILQDGGLQVVEK 0 0.0149 + High 153 0
1345.7718 6477 1345.7685 2.5 GTIQVITQGTSLK 0 0.0187 + 58.4 290 5
sp|Q71U36|TBA1A_HUMAN tubulin alpha-1A chain
1015.5805 5968 1015.5782 2.3 DVNAAIATIK 0 0.0538 + 4.5 11,321 2513
1380.6974 5847 1380.6980 0.4 LDHKFDLMYAK 1 0.0054 + 30.1 1786 59
1400.8227 5309 1400.8219 0.6 DVNAAIATIKTKR 2 0.2667 + 4.1 877 216
1457.8696 16,184 1457.8686 0.7 LIGQIVSSITASLR 0 0.0149 + High 57 0
1507.6710 9724 1507.6699 0.7 13 DSFNTFFSETGAGK 0 0.1012 + 7.7 23 3
1536.7840 5378 1536.7991 9.8 LDHKFDLMYAKR 2 0.2550  0.7 112 163
1552.7914 5455 1536.7991 4.6 2 LDHKFDLMYAKR 2 0.0152 + 3.6 233 64
1622.6928 10,812 1622.6969 2.5 13 DDSFNTFFSETGAGK 0 0.0149 + High 63 0
1718.8808 6237 1718.8820 0.7 NLDIERPTYTNLNR 1 0.0277 + 13.7 807 59
2008.8721 10,534 2007.8930 2.4 4 TIGGGDDSFNTFFSETGAGK 0 0.1681 + High 55 0
2185.8381 8495 2185.8414 1.5 14 DYEEVGVDSVEGEGEEEGEE 0 0.4562 + 4.8 34 7
2399.1689 10,388 2415.2051 4.3 1,4 QLFHPEQLITGKEDAANNYAR 1 0.1722 + 6.6 113 17
2416.2020 7906 2415.2051 5.3 4 QLFHPEQLITGKEDAANNYAR 1 0.0803 + 11.3 176 16
tr|F5H5D3|F5H5D3_HUMAN Uncharacterized protein (tubulin alpha-1C chain)
814.4665 5435 814.4669 0.5 APVISAEK 0 0.2742 + 1.6 62 38
1149.6202 5231 1149.6150 4.5 ATYAPVISAEK 0 0.1494  0.8 402 530
1221.6031 5836 1221.6110 6.5 NLDIERPTYT 1 0.0088 + 3.9 532 136
1241.5144 5244 1241.5103 3.3 GMEEGEFSEAR 0 0.1066 + 7.7 152 20
1285.6621 8031 1285.6634 1.0 DLEPTVIDEVR 0 0.0147 + 81.1 134 2
1309.6394 5455 1309.6131 20.1 TGKEDAANNYAR 1 0.2413 + 1.3 764 584
1448.7374 8034 1448.7380 0.4 NLDIERPTYTNL 1 0.8712 + 17.1 123 7
1679.7192 9832 1679.7183 0.5 GDDSFNTFFSETGAGK 0 0.0934 + 3.4 49 15
1689.7023 6470 1689.7060 2.2 YVGEGMEEGEFSEAR 0 0.7093 + 3.8 287 76
1705.6973 5522 1689.7060 4.8 2 YVGEGMEEGEFSEAR 0 0.2343 + 8.9 37 4
1718.8422 7066 1718.8820 23.2 NLDIERPTYTNLNR 1 0.0919 + 5.9 187 32
1736.7429 9841 1736.7398 1.8 GGDDSFNTFFSETGAGK 0 0.0350 + High 31 0
1825.9652 9180 1824.9854 2.3 4 VGINYQPPTVVPGGDLAK 0 0.0121 + 12.7 425 33
2008.8725 12,260 2007.8930 2.2 4 TIGGGDDSFNTFFSETGAGK 0 0.0779 + High 31 0
2398.1713 9981 2415.2051 3.0 1 QLFHPEQLITGKEDAANNYAR 1 0.0041 + 47.1 625 13
Note: MH+ indicates the protonated peptide mass. Amino acids with modiﬁcations are highlighted. Mod indicates modiﬁcation: (1) NH3, (2)
+O, (3) +COCH2, (4) –NH2 + OH, (5) non-tryptic, TA, (6) DP, (7) AS, (8) LT, (9) FQ, (10) TS, (11) QS, (12) SL, (13) GDD, (14) EY. Miss
indicates number of missed cleavages. In Up column, + indicates intensity GV>NV while  indicates intensity GV< NV.
186 Genomics Proteomics Bioinformatics 11 (2013) 182–194all the intensities measured for every peptide mass with a cer-
tain retention time in different samples [2]. There are a number
of open-source software applications for comparing Orbitrap
mass spectra from large numbers of samples in different
groups [3–5]. Open-source software applications running on
Windows operating system (OS), which combine the full spec-
tral MS1 peptide masses and protein identiﬁcations by frag-
mentation of peptide masses (MS2 or MS/MS), are scarce. A
few such examples are MsInspect, MSight, MSQuant and
MaxQuant [3–6]. The majority of open-source packages use
commercial search engines such as Mascot and Sequest to cor-
relate MS2 fragmentation spectra with proteins in *.fasta dat-
abases, such as MSQuant and the early version of MaxQuant
[4,6,7]. Other open-source software packages that compareMS1 spectra from various samples with each other can only
be installed on the Linux OS [5]. There are applications which
use statistics to ﬁrst determine differentially expressed MS1
peptide masses between the samples [8]. The masses that are
differentially expressed with peak intensities in the groups
are linked to a protein using MS2 fragmentation spectra.
Some applications determine relative quantities of a protein
between samples on the basis of the number of times that a
protein’s peptide sequence is detected in an MS2 scan in a
nano-LC Orbitrap measurement. For example, in MaxQuant
[7], for label-free quantiﬁcation, the maximum number of pep-
tides between any two samples is compared, resulting in a ma-
trix of protein ratios. There are a number of drawbacks
associated with this spectral count technique. The sequence
Table 2 Differentially expressed proteins with number of peptides between GV and NV groups
Classiﬁcation Protein name No. of
peptides
References Classiﬁcation Protein name No. of
peptides
References
Major blood proteins Fibrinogen 96 [11,12,14,16] Cytoskeleton Actin-related protein 2 4 [14]
Hemoglobin subunit alpha 22 [1,14] Actin-related protein 2/3
complex subunit 3
2 [14,15]
Ig kappa chain C 3 Actin-related protein 3 2 [14,15]
Serum albumin 22 [11] Alpha-internexin 2 [11]
Extracellular
matrix/cell membrane
Agrin 7 [10] Calponin-3 5 [13,16]
Alpha-1-antitrypsin 18 [11,14] Catenin beta-1 3
Alpha-2-macroglobulin 22 [14] Cell division control protein
42 homolog
2 [14]
Annexin A2 24 [12,14] Coﬁlin-1 6 [14]
Basement membrane-speciﬁc
heparan sulfate proteoglycan
core protein
25 [10,15] Collapsin response mediator
protein 4 long variant
14
Basigin 6 [14] Cytoplasmic dynein 1 heavy
chain 1
15
Brevican core protein 2 Cytoplasmic dynein 1 light
intermediate chain 2
2
CD44 antigen 5 [12] Cytoskeleton-associated
protein 4
10
CD99 antigen, isoform 4 Diﬀerentiation-related gene 1
protein
2
Cell surface glycoprotein
MUC18
3 Dihydropyrimidinase-related
protein 2
11 [14]
Chondroitin sulfate
proteoglycan 4
4 Ezrin 5 [11,13,14]
Collagen 43 [12] Fascin 6 [13]
Complement component C9 8 Gamma-adducin 2 [14]
Erythrocyte band 7 integral
membrane protein
4 [14] Glial ﬁbrillary acidic protein 135 [1,11,14]
Fibronectin 49 [1,11,12,14,15] Keratin, type II cytoskeletal
78
14
Galectin-3 4 [12] Lamin-B1 11 [13]
Glypican-1 3 [12] Microtubule-associated
protein
2
Integrin alpha-V light chain 4 [10,12] Microtubule-associated
protein 1B
38 [14]
Inter-alpha-trypsin inhibitor
heavy chain H1
8 Myosin regulatory light chain
12B
3 [14,15]
Inter-alpha-trypsin inhibitor
heavy chain H2
6 Nestin 27 [10]
Laminin 30 [10,12,14] Neuroﬁlament light
polypeptide
5
Major histocompatibility
complex, class I, C
2 Plectin 80 [14]
Neuronal membrane
glycoprotein M6-a
2 Proﬁlin-2 2 [11]
Nidogen-1 10 [10,14] Septin-7 4 [14]
Nidogen-2 5 [10,12,14] Septin-8 2
Periostin 16 [10,12,15] Spectrin alpha chain, non-
erythrocytic 1
25
Protein MAL2 3 Spectrin beta chain, brain 1 21 [14]
Reticulon-4 6 [14] Synemin 3
Tenascin 42 [10,12,15] Talin-1 21 [14]
Thrombospondin-1 4 [14,15] Transgelin-2 7 [14,15]
Thy-1 membrane glycoprotein 2 Tubulin 106 [11,14,15,22]
Transforming growth factor-
beta-induced protein ig-h3
9 [10,12,15] Vimentin 155 [1,11]
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Table 2 continued
Classiﬁcation Protein name No. of
peptides
References Classiﬁcation Protein name No. of
peptides
References
Vitronectin 12 [14] Protein folding/
chaperone/transport/
channel function
4F2 cell-surface antigen
heavy chain
3
Lipid and fatty acid
metabolic process
and regulation
3-Hydroxyacyl-CoA
dehydrogenase type-2
6 [14] 60 kDa heat shock protein,
mitochondrial
14 [14]
Acid ceramidase subunit beta 2 78 kDa glucose-regulated
protein
29 [14,15]
Enoyl-CoA hydratase 2 2 [14] Annexin A6 23
Fatty acid synthase 9 [14] Apolipoprotein E 6
Perilipin-3 7 Aquaporin-4 5 [11]
Peroxisomal multifunctional
enzyme type 2
2 [14] Band 3 anion transport
protein
9 [10]
Mitochondrial
transport
ADP/ATP translocase 2 10 Clusterin 15 [14]
ADP/ATP translocase 3 2 [15] Coatomer subunit alpha 3 [14]
Phosphate carrier protein,
mitochondrial
4 [14] Collagen-binding protein 2 4 [1,15,16]
Voltage-dependent anion-
selective channel protein 1
11 [12,14,15] Cytochrome b-245 heavy
chain
2
Voltage-dependent anion-
selective channel protein 2
4 [14] Cytochrome c oxidase
subunit 2
4
Metabolic enzymes 20,30-Cyclic-nucleotide 30-
phosphodiesterase
2 Electrogenic sodium
bicarbonate cotransporter
1
2
26S Protease regulatory
subunit 4
2 [14] Endoplasmic reticulum
resident protein 29
2
26S Proteasome non-ATPase
regulatory subunit 11
2 Excitatory amino acid
transporter 1
3
26S Proteasome non-ATPase
regulatory subunit 3
3 Fatty acid-binding protein,
brain
9 [1,11,13]
3-Ketoacyl-CoA thiolase 5 Heat shock cognate
71 kDa protein
17
6-Phosphogluconolactonase 2 [14] Heat shock protein HSP
90
57 [12,14,15]
Acetyl-CoA
acetyltransferase,
mitochondrial
3 Hsc70-interacting protein 3 [14]
Adipocyte plasma membrane-
associated protein
3 [14] Lactotransferrin 8
Alanyl-tRNA synthetase 4 [14] Prohibitin 7 [11,14]
Aldehyde dehydrogenase
family 1 member
2 [12] Ragulator complex
protein LAMTOR1
2
Alpha-enolase 7 [12,14] Serotransferrin 8 [14]
Amine oxidase (ﬂavin-
containing) B
9 [14] Sideroﬂexin 3 3
ATP synthase 38 [11,12,14] Solute carrier family 2
(facilitated glucose
transporter), member 1
3
ATP-dependent RNA
helicase DDX3Y
3 Sorting nexin 1, isoform 2
Coagulation factor XIII A
chain
7 [14] Sorting nexin-3 2 [14]
Cytosol aminopeptidase 3 T-complex protein 1 16 [10,14]
Cytosolic non-speciﬁc
dipeptidase
4 [14] V-type proton ATPase
subunit B, brain
2
D-3-phosphoglycerate
dehydrogenase
3 [13] Protein processing in
endoplasmic reticulum
40S ribosomal protein S23 6 [10,14,15]
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Table 2 continued
Classiﬁcation Protein name No. of
peptides
References Classiﬁcation Protein name No. of
peptides
References
Endonuclease domain-
containing 1 protein
4 [14] 60S ribosomal protein 5 [14,15]
Extracellular signal-
regulated kinase-2 splice
variant
4 ADP-ribosylation factor 3 2
Farnesyl pyrophosphate
synthase
3 Alpha-crystallin B chain 9 [11,13]
Fructose-bisphosphate
aldolase A
20 [14,15] Calnexin 11 [14]
Glutamate dehydrogenase 1,
mitochondrial
5 [10,11,14] Calreticulin 5 [14,15]
Glyceraldehyde-3-phosphate
dehydrogenase
15 [12,14,15] Coatomer protein
complex, subunit gamma
5
Glycogen phosphorylase,
brain
2 [14] Cullin-associated NEDD8-
dissociated protein 1
4 [14]
Haptoglobin 3 [14] Dolichyl-
diphosphooligosaccharide–
protein glycosyltransferase
6 [14,15]
Isocitrate dehydrogenase
(NADP)
3 [14] Elongation factor 1-gamma 4 [14,15]
L-lactate dehydrogenase 7 [14,15] Eukaryotic initiation factor
4A-I
4 [11,15]
Malate dehydrogenase,
mitochondrial
3 [14] Eukaryotic initiation
factor 4A-III
2
Methyltransferase-like
protein 7A
2 Eukaryotic translation
initiation factor 4H
3 [14]
NAD(P) transhydrogenase,
mitochondrial
6 [14] Heat shock 70 kDa
protein 9
10
Peptidylprolyl isomerase A
(Cyclophilin A)
3 Isoform 3 of
Heterogeneous nuclear
ribonucleoprotein Q
2 [15]
Peroxiredoxin-2 6 [14] Protein disulﬁde-isomerase 58 [11,14,15]
Phosphofructokinase,
platelet
2 Ubiquitin-conjugating
enzyme E2N
2 [14]
Phosphoglycerate kinase 12 [14] Vesicle-traﬃcking protein
SEC22b
3 [14]
Polyadenylate-binding
protein 1
5 Vesicular traﬃcking Clathrin heavy chain 1 14 [14,15]
Puromycin-sensitive
aminopeptidase-like protein
2 [14] Rab GDP dissociation
inhibitor alpha
6 [14,15]
Pyruvate kinase isozymes
M1/M2
35 [14,15] Ras-related protein Rab-10 3 [14]
Pyruvate kinase 6 [12] Ras-related protein Rab-
2A
3 [14]
Sarcoplasmic/endoplasmic
reticulum calcium ATPase 2
7 [14] Secernin 1, isoform 3
Splicing factor 3A subunit 3 2 [14] Transitional endoplasmic
reticulum ATPase
15 [14,15]
Thioredoxin-dependent
peroxide reductase,
mitochondrial
2 [14] Transmembrane emp24
domain-containing protein
10
7 [14,15]
Signal transduction 14-3-3 Protein beta/alpha 6 [14] Vesicle-fusing ATPase 4
14-3-3 Protein epsilon 26 [14] Other FACT complex subunit
SSRP1
3
14-3-3 Protein zeta/delta 4 [14,15] Isoform 4 of Myelin basic
protein
2
Adenylyl cyclase-associated
protein
4 [10,12] Receptor expression-
enhancing protein 5
2
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Table 2 continued
Classiﬁcation Protein name No. of
peptides
References Classiﬁcation Protein name No. of
peptides
References
Guanine nucleotide binding
protein (G protein), beta
polypeptide 2
4 Serine/arginine-rich
splicing factor 1
5
STAT1-alpha/beta 3 [15] Single-stranded DNA
binding protein 1, isoform
CRA_c
4
Vesicle-associated membrane
protein-associated protein A
2 [14]
Note: Proteins in bold indicate proteins that have previously been named in the literature as a tumor biomarker, or linked with angiogenesis. The
underlined proteins are also up-regulated in GT compared to NT.
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less often for peptide masses with a low intensity in the
MS1 spectrum [3]. The Xcalibur instrument software uses
exclusion criteria in a nano-LC MS measurement to exclude
selected MS1 parent masses for MS2 fragmentation in order
to obtain as many protein identiﬁcations as possible
(www.thermoscientiﬁc.com).
Performance of Peptrix was compared with that of MsIn-
spect [2] and the results were remarkably different, since the
software applications differ greatly in their techniques for pro-
cessing the mass spectra. Peptrix runs on an average computer
system with the Windows OS. Peptrix is written in Java and
uses around 1 GB of memory with a maximum memory heap
size, – Xmx1024 M, setting of the Java executable. Peptrix
does not use any statistics to make the peptide proﬁle matrix
[1]. Peptrix uses the freely available MS2 sequencing applica-
tion X!Tandem (http://www.thegpm.org/tandem/) [9] for link-
ing the protein identiﬁcations through MS2 peptide sequences
to the MS1 peptide masses. The interesting points and results
from this new link will be discussed.
Gliomas are among the most vascularized tumors. There-
fore, identiﬁcation of new angiogenesis-related proteins is
important for the development of anti-angiogenic therapies
[10]. A glioma type brain tumor dataset containing glioma and
endometrium control samples is analyzed using Peptrix in this
study. To discriminate between physiological and pathological
angiogenesis, protein expression proﬁles of proliferating vessels
in glioma are compared with those of endometrium tissue where
physiological angiogenesis takes place. The potential protein
biomarkers for glioma angiogenesis obtained are compared
with proteins that have previously been reported in the literature
[11–16]. The Orbitrap analysis results are also compared with
FT-ICR MS analysis results from a comparable sample set [1].Results
Peptrix performance
The processing of the 40 mass spectra in a peptide proﬁle ma-
trix shown in Figure 1 takes a total of 70.5 or 1.75 h per ﬁle on
average. A peptide proﬁle matrix for peptide masses with a se-
quence and protein label, and the average peak intensities of
the masses in the spectra for the groups GV, GT, NV and
NT are created. The peptide proﬁle matrix consists of 24,249
mass-retention time bins, of which 9248 (38%) have a sequenceand protein label. A large part of the low intensity peptide
masses in the MS1 spectra is not selected for MS2 sequencing
or sequencing is not successful. Among the 24,249 peptides,
52% are up-regulated with intensity ratio GV/NV> 1 (+),
and 48% were down-regulated with intensity ratio GV/
NV< 1 ().
The instrumental coefﬁcient of variance (CV) of the Orbi-
trap mass spectrometer is 10% for measurements of high
intensity peaks of technical replicates [2]. When working with
peak lists, peak ﬁnding and matching low intensity peaks in-
crease the CV. The average CV of measured peak intensities
of technical replicates is 25% for Peptrix [2]. The biological
variability of peak intensities is large. The CV of peak intensi-
ties when measured for all samples of a group, 7350 times in
the 24,249 mass retention time bins of the peptide proﬁle ma-
trix, is about 100% of the mean intensity.
A small selection of proteins that have differentially ex-
pressed peptide peak intensities between GV and NV is shown
in Table 1. The average spectrum peak intensities for the pep-
tide masses for myosin-9 in the four groups examined are
shown in Table S1. The average mass accuracy of all identiﬁed
peptide masses was 4 ppm compared to the calculated value.
The Orbitrap peptide masses are approximately less accurate
by a factor of 4–7 than those measured with FT-ICR MS.
The number of unique sequences is 6911 in the Orbitrap
peptide proﬁle matrix, which means that sequences appear
redundant 1.3 times on average in the matrix. The number
of peptide sequences divided by the number of unique se-
quences is 9248/6911  1.3. Majority of the sequences appear
once (about 85%) or twice (about 10%), while some sequences
appear three times (about 4%) or more (about 1%) (Tables 1
and S1).
There are three reasons why peptide sequences appear in
the peptide proﬁle matrix more than once. Firstly, in approx-
imately 40% of cases, the repetition of the sequences is caused
by tailing possibly combined with mismatching of the peptide
mass with other masses in the elution proﬁle for the nano-LC.
For example, the sequence FSVNLDVK for protein CRY-
AB_HUMAN (alpha-crystallin B chain) is shown twice
with a difference in retention time binning of 1408 s
(7157  5749 s), which is >300 s (5 min) (Table 1). Another
example is the peptide mass with the sequence IAQLEEQLD-
NETK for myosin-9 in Table S1. The difference in retention
time between two bins is 1357 s (7199  5842 s), which is
>300 s (5 min) too. Secondly, in approximately 40% of cases,
the sequence is present more often in the peptide proﬁle matrix
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QEEEMMAKEEELVK for myosin-9 is present in three mass
retention time bins in Table S1, i.e., with mass 1705.7642,
1721.7544 and 1722.7951 Da. The mass of the peptide without
modiﬁcation is 1722.7951 Da. The ﬁrst modiﬁcation of peptide
with mass 1705.7642 Da is an N-terminal loss of NH3 with
17.0265 Da and cyclization of glutamine (Q) [17], while the
secondmodiﬁcation of peptidewithmass 1721.7544 Da is an ex-
tra oxidation of methionine (M), which leads to an increase of
the mass by 15.999 Da (net change 15.999–17.0265  1 Da).
Finally, in approximately 20% of cases, the sequence is mea-
sured more often because of faults in the determinations or mis-
matching of the masses of the peptides. The mass difference is
slightly greater than 10 ppm and the peptide appears in a differ-
entmass retention time bin in thematrix, while it should be pres-
ent in one bin. The peptide with sequence YSVQTADHR for
fascin (Table 1) is such an example. The difference in mass is
17 ppm (>10 ppm binning), while the retention time binning
is not more than 5 min different, i.e., the bins differ by
5880  5760 = 120 s.
The number of unique proteins linked to the peptide proﬁle
matrix is 1873. Each protein is identiﬁed with approximately 4
(6911/1873) unique peptide sequences. The MS2 protein labels
from the peak lists from the individual samples are currently
passively matched with the MS1 peptide proﬁle matrix in the
last step of the process shown in Figure 1. The number of un-
ique peptide sequences in the peak lists from the individual
samples is 10,259 and the number of protein labels is 2569.
The peptide proﬁle matrix has approximately 67% (6911/
10,259) of the peptide sequence and 73% (1873/2569) of the
protein information from the peak lists from the individual
samples.
Modiﬁcations detected by X!Tandem
Compared to the commercial search engine Mascot, the search
engine X!Tandem detects a large number of non-tryptic pep-
tide fragments due to a different search algorithm employed,
approximately 11% of the total (Tables 1 and S1). Two such
examples are the sequence DYEEVGVDSVEGEGEEEGEE
from tubulin alpha-1A chain split at EY (Table 1) and the se-
quence KTELEDTLDSTAAQQELR from myosin-9 split at
LK in Table S1.
Approximately 20% of the sequences have a modiﬁcation
(Tables 1 and S1). In approximately 1/3 of the cases, this in-
volves an N-terminal loss of –NH3 and cyclization of Q for
17.0265 Da, while in approximately 1/3 of the cases, oxidation
ofM (+O) adds+15.999 Da. In addition, in approximately 1/4
of the cases there occurs deamidation (NH2 + OH) of aspar-
agine (N) or Q to increase +0.984 Da, and in some cases (the
remaining approximately 1/10), acetylation (+COCH2) of M
or alanine (A) confers an augmentation of +42.0106 Da.
An N-terminal loss of –NH3 and Q cyclization increases the
hydrophobicity of the peptide. Consequently, the retention
time of the peptide masses clearly increases by approximately
2200 s (36 min) through this N-terminal loss [17]. For peptide
with sequence QAQQERDELADEIANSSGK from myosin-9,
the increased retention time is 7610  5496 = 2114 s and
7610  5363 = 2247 s (Table S1). There are two different val-
ues due to binning (errors), since the retention times 5496 and
5363 should have been in one mass-retention time bin.From all observed modiﬁcations, only M oxidation is given
as an input variable in the graphical user interface (GUI) of
Peptrix. Peptrix stores the modiﬁcations in the ﬁle default_in-
put.xml used by tandem.exe (Figure 1). The other modiﬁca-
tions are detected by X!Tandem as standard, when the
template default_input.xml is used, which can be downloaded
together with tandem.exe in the distribution of X!Tandem.
The default_input.xml can be changed according to personal
needs. The modiﬁcations including N-terminal loss of ammo-
nia and Q cyclization, oxidation of M, acetylation of M or
A, as well as which amino acid this concerns, are reported in
the ﬁle output.xml (Figure 1). The deamidation of N or Q is
not detected as such, but is reported as an increase of mass
of approximately 1 Da, compared to the theoretical mass.
Selection of candidate biomarkers for glioma angiogenesis
Candidate biomarkers for glioma angiogenesis (Table S2) are
selected from the peptide proﬁle matrix based on the following
criteria: (1) at least two unique peptide sequences are up-regu-
lated in the GV versus NV group with intensity ratio GV/
NV> 1 (+). This results in 597 protein labels, which are
about 32% of the total number of 1873 protein labels; (2) no
more than 1 of 6 sequences exclusively down regulated for each
protein (), this is 17% of the peptide sequences for each pro-
tein. This results in 328 protein labels, which are about 18% of
the total number of protein labels; (3) at least one or preferably
more peptides with a Wilcoxon–Mann–Whitney P va-
lue < 0.1. This results in 235 protein labels (Table S2), which
are about 13% of the total number of protein labels.
Apparent down-regulated peptide masses with intensity
GV< NV () due to tailing in retention time are not consid-
ered. In most cases, the peptides of proteins that are up-regu-
lated in GV are also up-regulated with peak intensities
GV > NV (+). For some sequences of peptide masses in Ta-
ble 1, a different pattern can be observed with peptide peak
intensity GV <NV (). This usually concerns sequences that
appear more than once in the peptide proﬁle matrix through
tailing of the peptide mass in the elution proﬁle from LC, mod-
iﬁcations of the peptide or errors in determining the mass.
Such examples include the sequences YSVQTADHR from fas-
cin, LTNSQNFDEYMK from fatty acid-binding protein,
brain, LGVRPSQGGEAPR and SYTITGLQPGTDYK from
ﬁbronectin and LDHKFDLMYAKR from tubulin alpha-1A
chain.
Proteins can be selected from the list of 235 up-regulated
protein labels (Table S2) and proteins that were previously
named in the literature as a tumor biomarker or linked with
angiogenesis [1,10–16] are displayed in bold in Table 2. The
up-regulated proteins in GV were classiﬁed according to a
scheme set-up [15] and information provided at www.uni-
prot.org. As presented in Table 2, a large number of proteins
are cytoskeleton proteins, involved in cell migration and cell
shape or cross linking of actin [1] in bundles, the ﬁlopodia
[18], such as fascin, cell division control protein 42 homolog
and spectrin beta chain, brain 1. Fibronectin (Table 2) is an
example of the KEGG hsa04512 ECM–receptor interaction
pathway, connecting with cell surface protein integrins, regu-
lating cell-to-ECM and cell-to-cell adhesion. Other members
of this pathway including agrin, integrin, laminin, tenascin
[10,12,14,15] are also listed in Table 2.
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lected from the list of up-regulated proteins in Table 2, but need
to be validated independently. For example, clusterin was previ-
ously reported to be related tomultiple sclerosis [19], while excit-
atory amino acid transporter 1 is perhaps associated with the
glutamate dehydrogenase 1, mitochondrial (Accession No.
P00367, Table S2) [10,11], since both glutamate transporters
and glutamate dehydrogenase play roles in the developing brain
[20]. In addition, 3-hydroxyacyl CoAdehydrogenase is an exam-
ple of a candidate involved in the lipid and fatty acid metabolic
process and regulation. It is interesting to note that angiogenesis
and metastasis are reduced by the inhibition of fatty acid syn-
thase with the anti obesity drug Orlistat [21].
In the previous study, the comparison of GT and NT also
shows a sharp skewed distribution toward low Wilcoxon–
Mann–Whitney P values [2]. A large number of peptides are
differentially expressed between GT and NT. These proteins
are underlined in Table 2. 69 of the selected 235 protein labels
(29%) appear also up-regulated in GT, compared to NT. Dif-
ferences observed between GV and GT are not presented in
Table 2, while no signiﬁcant differences appear between NV
and NT at all [2].
The candidate biomarker Cdc42 effector protein 3 [1] is not
found in the peptide proﬁle matrix. Peptide sequences from
Cdc42 effector protein 4 (B3KUS7) are however deﬁned in the
peak lists of GV. The peak intensity of a peptide mass with se-
quence TPFLLVGTQIDLR from a related protein Cdc42
homolog (E7ETU3) is up-regulated in GV compared to NV
with a factor of 17.2 (Table 1). Myosin-9 [15] is also not present
in the list of selected candidates. The considerably lower Wilco-
xon–Mann–Whitney P values and greater intensity ratios GV/
NV measured by FT-ICR [1] are not observed in the present
analysis. The Wilcoxon–Mann–Whitney P values between GV
and NV of peptide masses (marked with * in Table S1) remain
constantly high at about 0.6 from position 712 up to position
1755 of the primary structure of myosin-9. In addition, annexin
A5 [1,12,14] is up-regulated in GV compared to NV, but absent
from the list of selected candidates in Table 2, due to lack of pep-
tide mass with Wilcoxon–Mann–Whitney P value < 0.1. Dif-
ferent from an earlier ﬁnding [1], desmin (Swiss-Prot
Accession code P17661) does not appear to be up-regulated in
GV compared to NV, but is instead down-regulated () as re-
ported in another study [15]. The down regulation of desmin
could be attributed to the use of a different control sample set,
proliferating endometrium (representing physiological angio-
genesis) instead of the normal control hemispheric brain used
in the FT-ICR study. Even so, desmin is related to angiogenic
micro vessels and is localized together with vimentin, a marker
for pericytes [15,22].
Estimation of the FDR
The false discovery rate (FDR) of a protein is estimated based
on how many single peptides of the protein are up- or down
regulated.
All proteins mentioned in Table S2 are taken up-regulated
and the majority of the proteins have been reported to be asso-
ciated with tumor growth in the literature (Table 2). The 235
protein labels represent 2133 mass intensity bins in the peptide
proﬁle matrix (Table S2), from which 312 appear down-
regulated () in GV versus NV group. The chance of havinga single peptide measured as down-regulated by mistake is esti-
mated as 0.15 (312/2133) for an assumed up-regulated protein.
Since approximately half of the peptides are either up-reg-
ulated or down-regulated in the peptide proﬁle matrix, the
FDR is therefore set as 0.15. The FDR of protein with two po-
sitive (+) peptides is 0.02. The FDR of fascin (Table 1) found
with 5 positive (+) and one negative () peptide for example is
0.0004 [(0.15)5 · (0.85) · 6!/(5! · 1!)].
Discussion
Peptrix implements the MS2 sequencing application X!Tan-
dem and detects label-free differentially expressed candidate
biomarkers for angiogenesis in a small dataset, by comparing
the average peak intensities in combination with the non-para-
metric Wilcoxon–Mann–Whitney test. In this way, Peptrix is
capable of detecting meaningful biomarkers, despite the large
biological variability of peak intensities and zero values (pep-
tide peak intensity is below detection limit or peak detection
fails). As a result, biomarkers that have been reported previ-
ously in the literature are identiﬁed.
Peptide proﬁling from OrbitrapMS ﬁles results in less pro-
nounced intensity ratios between GV and NV than with previous
FT-ICR measurements. There is therefore no sign (Table S1) of
the supposed up-regulation of peptide masses on the C-terminus
of myosin-9 [1]. The level of up-regulation can now be determined
with peptidemasses atmore positions in the protein, becausemore
peptidemasses are measured frommyosin-9 through LC separa-
tion than those measured by FT-ICR.
The lower mass accuracy of OrbitrapMS compared to FT-
ICRMS is compensated by greater number of masses and pro-
tein identiﬁcations, which can be directly linked to the peptide
proﬁle matrix. Through LC separation, the Orbitrap peptide
proﬁle matrix contains approximately 10 times more bins
(24,249/2275) than the FT-ICR peptide proﬁle matrix obtained
from a comparable dataset. The signal is averaged over more
MS1 measurements than with FT-ICR MS as well.
A distorted image of up- or down-regulated peptide masses
from a protein is however sometimes created through tailing,
modiﬁcations, incorrectly-determinedmasses andmismatching.
Peptide masses from up-regulated protein intensity GV> NV
(+) in some mass retention time bins can appear down-regu-
lated with intensity GV <NV (). The peptide matrix contains
approximately 70%of theMS2 labels of the individual peak lists
together. Loss of MS2 sequencing information occurs when
matching the individual peak lists in the last step of the creation
of the peptide proﬁle matrix (Figure 1). It is therefore important
not to match the MS2 sequencing information passively, but to
actively involve it in the creation of the matrix, so that all MS2
sequencing information is retained. This active matching should
be implemented while retaining maximal speed of Peptrix and
the minimal memory usage of the work station.
Materials and methods
Dataset
A glioma type brain tumor dataset containing glioma and
endometrium control samples is analyzed in this study. The
dataset consists of 10 micro-dissected tissue samples from
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vessels (GT), 10 from normal endometrium blood vessels
(NV), and 10 from endometrium tissue around these blood
vessels (NT). The origins and preparation of the micro-dis-
sected tissue samples are described in [10]. In the present anal-
ysis, NV and NT of proliferating endometrium (representing
physiological angiogenesis) are used as control samples [10],
whereas normal control hemispheric brain samples were used
in the FT-ICR study [1,16].
Peptrix label-free peptide proﬁling software
The Orbitrap MS measurements are described previously in
[2,10]. Forty *.RAW ﬁles exported by the Xcalibur instrument
software with an average size of 523 MB are imported in Pep-
trix for analysis. The Peptrix architecture is described in [23].
The imported *.RAW ﬁles are saved on an FTP server. Re-
cords with the ﬁle names of these *.RAW are created in the
Table Sample in a MySQL database (Supplementary File 1).
The ﬁles are assigned to GV, GT, NV or NT group, respec-
tively, in the Java Swing graphic user interface (GUI) of Pep-
trix. The links between ﬁle name and group code are saved as
records in the table Results of the MySQL database (Supple-
mentary File 1). The mass and retention time window for bin-
ning the peptide masses in the peptide proﬁle matrix, which is
set as 10 ppm and 5 min, respectively, are entered in the GUI.
The expected modiﬁcations of the peptide masses can also be
entered. Only the (ﬁxed) modiﬁcation carbamidomethyl cys-
teine (C), mass + C2H3NO 57.022 Da, and (variable) oxida-
tion of M, mass + O 15.999 Da, are currently implemented.
The precursor mass tolerance of the parent peptide and MS2
fragment mass tolerance, which are set as 10 ppm and
0.6 Da, respectively, are entered in the GUI.
The processing of the MS ﬁles is displayed in Figure 1,
which is done by pressing the button once without any further
user interaction. Peptrix uses the following applications and
ﬁles invisibly: (1) R.exe (http://www.r-project.org/) to trace
differentially expressed peptides in the groups with the Wilco-
xon–Mann–Whitney module; (2) Readw.exe (version 4.3.1,
http://sourceforge.net/projects/sashimi/ﬁles/) for converting
the *.RAW ﬁles into *.mzXML ﬁles; (3) the *.fasta ﬁle and
HUMAN.fasta in this study, which is the text database to cor-
relate MS2 fragmentation masses to a protein and (4) tan-
dem.exe to search for the most likely protein. Tandem.exe
reads both Mascot generic ﬁles, *.MGF, with the peptide par-
ent mass and the MS2 fragmentation masses, and the 38.1 MB
HUMAN.fasta ﬁle. TheHUMAN.fasta ﬁle can be downloaded
as HUMAN.fasta.gz archive (ftp://ftp.uniprot.org/pub/dat-
abases/uniprot/) in the directory current_release/knowledge-
base/proteomes/. Peptrix generates a MGF ﬁle for each
Orbitrap ﬁle.
At ﬁrst, a pop-up window is displayed by Peptrix to
search for the ﬁles and programs in the computer ﬁle sys-
tem: (1) R.exe; (2) Readw.exe (version 4.3.1); (3) *.fasta ﬁle
and (4) tandem.exe. The paths to the ﬁles in the ﬁle system
and ﬁle names are saved as records in the Table Itemvalue of
the MySQL database (Supplementary File 1). Peptrix once
again prompts for the ﬁle or the program when the ﬁles
or programs are not found in a subsequent analysis, for
example, because they have been deleted from the computer
ﬁle system.Availability and requirements
Peptrix is freely available. It requires Microsoft Windows 2000
OS or higher, R (R-2.15.1-win.exe or higher), Quick ‘n Easy
FTP Server Lite version 3.2 or higher, MySQL 5.5.27 (mys-
ql-5.5.27-win32.msi) or higher database, Java Runtime Envi-
ronment (JRE) 7 Update 7 or higher (jre-7u7-windows-
i586.exe), Eclipse Classic (Eclipse Juno 4.2.0) – Windows,
edtftpj-2.3.0 or higher (edtftpj.jar), Connector/J (mysql-con-
nector-java-5.1.22-bin.jar or higher), X!Tandem (tandem-
win-11-12-01-1.zip) (tandem.exe), HUMAN.fasta (HUMAN.
fasta.gz) and Readw.exe (version 4.3.1) (ReAdW-4.3.1.zip)
for running. The source code of Peptrix is available as a zip ﬁle
(http://sourceforge.net/projects/peptrix/ﬁles/), as well as the
database script (Supplementary File 1), with detailed installa-
tion and running instructions and URLs of the software pro-
viders. The raw Orbitrap ﬁles conversion to mzXML
formatted ﬁles was tested with Readw.exe version 4.3.1. Be-
cause the Readw.exe program depends on Windows-only ven-
dor libraries from Thermo, the code for Orbitrap data
handling will only work under Windows with Thermo Fischer
Scientiﬁcs’ Xcalibur software installed. If the Readw.exe pro-
gram does not work properly, zlib1.dll should be downloaded
(http://sourceforge.net/projects/peptrix/ﬁles/). The library
zlib1.dll can be placed in the c:/windows/system32/directory
and ‘‘regsvr32 c:/windows/system32/zlib1.dll’’ or ‘‘regsvr32
zlib1.dll’’ can be executed in the Windows command prompt
(MSDOS box). If a 64-bit version of Windows is used, zlib1.dll
should be copied in C:/Windows/SysWOW64/.
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